Sign In
Buy INZY
$4.00
+0 (+0%)
At Close: Sep 30, 2025
Inozyme Pharma Announces Closing of Initial Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
08:01pm, Thursday, 30'th Jul 2020
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (“Inozyme”) (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of a
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 27)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)
Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO)...
U.S. IPO Weekly Recap: Software And SPACs Shine In A 7-IPO Week
04:22pm, Saturday, 25'th Jul 2020
Seven IPOs and five SPACs entered public markets this past week, led by high-flying Jamf Holding and the largest SPAC ever Pershing Square Tontine Holdings.
IPO Update: Inozyme Pharma Readies IPO Effort
03:12pm, Monday, 20'th Jul 2020
Inozyme Pharma has filed to raise $75 million in a U.S. IPO.
U.S. IPO Weekly Recap: 3 IPOs Close Out The 2Q In Shortened Holiday Week
02:28pm, Friday, 03'rd Jul 2020
Three IPOs raised $2.3 billion this past week, led by Dun & Bradstreet's billion-dollar deal. All three IPOs upsized their deals and priced above the range. Lem
